Home > Press > Starpharma's DNT Priostar(TM) Dendrimers Significantly Improve Properties of Marketed Fluorescent Reagents
Starpharma (ASX:SPL, OTCQX: SPHRY), through its US subsidiary company Dendritic
Nanotechnologies Inc (DNT), has found that DNT's Priostar(TM) dendrimer
technology can be used to amplify the signal and increase the duration of
the signal (photostability) of existing products in the multi-billion
dollar fluorescent reagents market. The company has filed a patent for the
discovery through DNT.
Starpharma's DNT Priostar(TM) Dendrimers Significantly Improve Properties of Marketed Fluorescent Reagents
MELBOURNE, Australia | Posted on May 7th, 2007
Fluorescent reagents are used extensively in laboratories for high-
throughput screening, diagnostic immunoassays, microarrays, fluorescence
microscopy, genomics and proteomics. Strong signals and photostability are
extremely important properties as they increase the sensitivity of
detection methods and facilitate measurement of the signal, respectively.
Increased sensitivity is needed to study disease markers that are
present at very low levels -- often below those detectable with current
Using its Priostar(TM) technology, DNT has created dye-dendrimer
complexes from various commercial dyes that show significantly enhanced
fluorescent (greater than 10 fold) and photostability (greater than 4
fold), in addition to improved solubility in water.
Preliminary testing has shown that the enhanced properties of
Priostar(TM) dendrimer-dye complexes are retained after attachment to an
antibody, an integral component for many of the applications of fluorescent
"Market feedback indicates that the scientific community and industry
users of these products will highly value the availability of reagents with
increased sensitivity and photostability," said Dr. Lori Reyna, director of
life sciences at DNT. Scientists are always keen to increase the
sensitivity of detection and quantitation methods."
DNT will partner with established leaders in the diagnostic and
research reagent industries through licensing and supply agreements. The
initial commercialization target will be the research reagent and in vitro
diagnostic markets. DNT is currently in preliminary commercialization
discussions with the market leaders in the area of fluorescence reagents.
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in
the development of dendrimer nanotechnology for pharmaceutical,
life-science and other applications. SPL is principally composed of two
operating companies, Starpharma Pty Ltd in Melbourne, Australia and
Dendritic Nanotechnologies, Inc in Michigan, USA.
For more information, please click here
Tel: +61 2 9237 2800
Mob: +61 417 382 391
Dr Jackie Fairley
Chief Executive Officer Starpharma Holdings Ltd
+61 3 8532 2704
Dr Robert Berry
Starpharma Holdings Ltd
+61 3 8532 2702
Copyright © PR Newswire Association LLC.
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Researchers create vaccine for dust-mite allergies Main Page Content: Vaccine reduced lung inflammation to allergens in lab and animal tests July 22nd, 2014
NIST shows ultrasonically propelled nanorods spin dizzyingly fast July 22nd, 2014
SentiMag® Now Available in Australia and New Zealand July 21st, 2014
More than glitter: Scientists explain how gold nanoparticles easily penetrate cells, making them useful for delivering drugs July 21st, 2014
Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 July 23rd, 2014
UCF Nanotech Spinout Developing Revolutionary Battery Technology: Power the Next Generation of Electronics with Carbon July 23rd, 2014
Deadline Announced for Registration in 7th Int'l Nanotechnology Festival in Iran July 23rd, 2014
A Crystal Wedding in the Nanocosmos July 23rd, 2014
Production of Non-Virus Nanocarriers with Highest Amount of Gene Delivery July 17th, 2014
Physicists Use Computer Models to Reveal Quantum Effects in Biological Oxygen Transport: The team solved a long-standing question by explaining why oxygen – and not deadly carbon monoxide – preferably binds to the proteins that transport it around the body. July 17th, 2014
Tiny DNA pyramids enter bacteria easily -- and deliver a deadly payload July 9th, 2014
Artificial cilia: Scientists from Kiel University develop nano-structured transportation system July 4th, 2014